Annual Total Liabilities
$103.53 M
-$3.52 M-3.29%
December 31, 2023
Summary
- As of February 7, 2025, VNDA annual total liabilities is $103.53 million, with the most recent change of -$3.52 million (-3.29%) on December 31, 2023.
- During the last 3 years, VNDA annual total liabilities has risen by +$23.34 million (+29.11%).
- VNDA annual total liabilities is now -97.71% below its all-time high of $4.52 billion, reached on December 1, 2003.
Performance
VNDA Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$103.89 M
-$4.96 M-4.56%
September 30, 2024
Summary
- As of February 7, 2025, VNDA quarterly total liabilities is $103.89 million, with the most recent change of -$4.96 million (-4.56%) on September 30, 2024.
- Over the past year, VNDA quarterly total liabilities has dropped by -$4.79 million (-4.41%).
- VNDA quarterly total liabilities is now -48.74% below its all-time high of $202.68 million, reached on December 31, 2009.
Performance
VNDA Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
VNDA Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -3.3% | -4.4% |
| 3 y3 years | +29.1% | -4.4% |
| 5 y5 years | +82.6% | -4.4% |
VNDA Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -3.3% | +16.5% | -4.6% | +16.9% |
| 5 y | 5-year | -3.3% | +42.2% | -4.6% | +44.0% |
| alltime | all time | -97.7% | +5624.0% | -48.7% | +2554.6% |
Vanda Pharmaceuticals Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $103.89 M(-4.6%) |
| Jun 2024 | - | $108.86 M(+0.2%) |
| Mar 2024 | - | $108.69 M(+5.0%) |
| Dec 2023 | $103.53 M(-3.3%) | $103.53 M(+5.1%) |
| Sep 2023 | - | $98.50 M(-3.2%) |
| Jun 2023 | - | $101.78 M(-6.4%) |
| Mar 2023 | - | $108.79 M(+1.6%) |
| Dec 2022 | $107.05 M(+20.5%) | $107.05 M(+0.9%) |
| Sep 2022 | - | $106.13 M(+5.5%) |
| Jun 2022 | - | $100.55 M(-0.9%) |
| Mar 2022 | - | $101.44 M(+14.1%) |
| Dec 2021 | $88.86 M(+10.8%) | $88.86 M(+2.8%) |
| Sep 2021 | - | $86.45 M(+0.0%) |
| Jun 2021 | - | $86.42 M(+14.4%) |
| Mar 2021 | - | $75.56 M(-5.8%) |
| Dec 2020 | $80.19 M(+10.1%) | $80.19 M(+6.4%) |
| Sep 2020 | - | $75.33 M(+0.4%) |
| Jun 2020 | - | $75.05 M(+4.0%) |
| Mar 2020 | - | $72.14 M(-0.9%) |
| Dec 2019 | $72.80 M(+28.4%) | $72.80 M(-1.0%) |
| Sep 2019 | - | $73.54 M(-3.0%) |
| Jun 2019 | - | $75.79 M(+4.2%) |
| Mar 2019 | - | $72.76 M(+28.3%) |
| Dec 2018 | $56.71 M(-23.4%) | $56.71 M(+12.2%) |
| Sep 2018 | - | $50.52 M(-2.2%) |
| Jun 2018 | - | $51.66 M(-32.2%) |
| Mar 2018 | - | $76.17 M(+2.9%) |
| Dec 2017 | $74.04 M(-6.3%) | $74.04 M(-1.6%) |
| Sep 2017 | - | $75.24 M(-5.1%) |
| Jun 2017 | - | $79.25 M(+3.5%) |
| Mar 2017 | - | $76.58 M(-3.1%) |
| Dec 2016 | $79.04 M(-1.2%) | $79.04 M(-0.3%) |
| Sep 2016 | - | $79.28 M(-1.4%) |
| Jun 2016 | - | $80.42 M(-3.9%) |
| Mar 2016 | - | $83.73 M(+4.6%) |
| Dec 2015 | $80.02 M(+635.0%) | $80.02 M(+7.3%) |
| Sep 2015 | - | $74.61 M(+0.9%) |
| Jun 2015 | - | $73.95 M(+20.9%) |
| Mar 2015 | - | $61.17 M(+461.8%) |
| Dec 2014 | $10.89 M(-89.0%) | $10.89 M(-86.1%) |
| Sep 2014 | - | $78.11 M(-8.4%) |
| Jun 2014 | - | $85.29 M(-14.7%) |
| Mar 2014 | - | $100.00 M(+0.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2013 | $99.22 M(-21.0%) | $99.22 M(-5.6%) |
| Sep 2013 | - | $105.09 M(-6.1%) |
| Jun 2013 | - | $111.93 M(-5.7%) |
| Mar 2013 | - | $118.66 M(-5.5%) |
| Dec 2012 | $125.54 M(-15.8%) | $125.54 M(-6.6%) |
| Sep 2012 | - | $134.46 M(-4.5%) |
| Jun 2012 | - | $140.75 M(-3.4%) |
| Mar 2012 | - | $145.68 M(-2.3%) |
| Dec 2011 | $149.14 M(-15.0%) | $149.14 M(-5.6%) |
| Sep 2011 | - | $158.06 M(-3.6%) |
| Jun 2011 | - | $163.90 M(-3.5%) |
| Mar 2011 | - | $169.76 M(-3.2%) |
| Dec 2010 | $175.37 M(-13.5%) | $175.37 M(-4.3%) |
| Sep 2010 | - | $183.20 M(-5.0%) |
| Jun 2010 | - | $192.84 M(-3.2%) |
| Mar 2010 | - | $199.29 M(-1.7%) |
| Dec 2009 | $202.68 M(+5078.9%) | $202.68 M(+2177.8%) |
| Sep 2009 | - | $8.90 M(-24.8%) |
| Jun 2009 | - | $11.84 M(+197.1%) |
| Mar 2009 | - | $3.98 M(+1.8%) |
| Dec 2008 | $3.91 M(-70.2%) | $3.91 M(-12.6%) |
| Sep 2008 | - | $4.48 M(-56.0%) |
| Jun 2008 | - | $10.17 M(-5.3%) |
| Mar 2008 | - | $10.74 M(-18.2%) |
| Dec 2007 | $13.13 M(+38.2%) | $13.13 M(-15.8%) |
| Sep 2007 | - | $15.60 M(+68.0%) |
| Jun 2007 | - | $9.29 M(+26.1%) |
| Mar 2007 | - | $7.36 M(-22.5%) |
| Dec 2006 | $9.50 M(+86.8%) | $9.50 M(-8.0%) |
| Sep 2006 | - | $10.33 M(-39.9%) |
| Jun 2006 | - | $17.20 M(+54.6%) |
| Mar 2006 | - | $11.13 M(+118.7%) |
| Dec 2005 | $5.09 M(+181.3%) | $5.09 M |
| Dec 2004 | $1.81 M(-100.0%) | - |
| Dec 2003 | $4.52 B(+3.8%) | - |
| Dec 2002 | $4.35 B(+59.6%) | - |
| Dec 2001 | $2.73 B(-3.8%) | - |
| Dec 2000 | $2.84 B(+28.8%) | - |
| Dec 1999 | $2.20 B(-0.4%) | - |
| Dec 1998 | $2.21 B(+114.2%) | - |
| Dec 1997 | $1.03 B(+257.1%) | - |
| Dec 1996 | $288.90 M(-2.8%) | - |
| Dec 1995 | $297.20 M(+7.4%) | - |
| Dec 1994 | $276.80 M | - |
FAQ
- What is Vanda Pharmaceuticals annual total liabilities?
- What is the all time high annual total liabilities for Vanda Pharmaceuticals?
- What is Vanda Pharmaceuticals annual total liabilities year-on-year change?
- What is Vanda Pharmaceuticals quarterly total liabilities?
- What is the all time high quarterly total liabilities for Vanda Pharmaceuticals?
- What is Vanda Pharmaceuticals quarterly total liabilities year-on-year change?
What is Vanda Pharmaceuticals annual total liabilities?
The current annual total liabilities of VNDA is $103.53 M
What is the all time high annual total liabilities for Vanda Pharmaceuticals?
Vanda Pharmaceuticals all-time high annual total liabilities is $4.52 B
What is Vanda Pharmaceuticals annual total liabilities year-on-year change?
Over the past year, VNDA annual total liabilities has changed by -$3.52 M (-3.29%)
What is Vanda Pharmaceuticals quarterly total liabilities?
The current quarterly total liabilities of VNDA is $103.89 M
What is the all time high quarterly total liabilities for Vanda Pharmaceuticals?
Vanda Pharmaceuticals all-time high quarterly total liabilities is $202.68 M
What is Vanda Pharmaceuticals quarterly total liabilities year-on-year change?
Over the past year, VNDA quarterly total liabilities has changed by -$4.79 M (-4.41%)